A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Endocrine-Related Cancer

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1530/ERC-14-0190PMID 25015994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

  2014cited by this paper
• Molecular pathology and genetics of gastrointestinal neuroendocrine tumours

  2014cited by this paper
• Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma

  2014cited by this paper
• Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.

  2014influential reference
• Theranostic and molecular classification of breast cancer.

  2014cited by this paper
• Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors

  2014cited by this paper
• Cancer Risk Assessment Using Genetic Panel Testing: Considerations for Clinical Application

  2014cited by this paper
• Pancreastatin is an endogenous peptide that regulates glucose homeostasis.

  2013cited by this paper
• The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study

  2013cited by this paper
• Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors

  2013influential reference
• The evolving landscape of neuroendocrine tumors.

  2013cited by this paper
• A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress.

  2013cited by this paper
• Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?

  2013cited by this paper
• Current methods for fluorescence-based universal sequence-dependent detection of nucleic acids in homogenous assays and clinical applications.

  2013cited by this paper
• Evaluation of a Multiplex Assay for Estimation of HIV-1 Incidence

  2013cited by this paper
• Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility

  2013influential reference
• Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches

  2013cited by this paper
• Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients.

  2013cited by this paper
• A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells

  2013influential reference
• Systemic therapeutic options for carcinoid.

  2013cited by this paper
• The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood

  2013influential reference
• Molecular Profiling for Breast Cancer: A Comprehensive Review

  2013cited by this paper
• Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.

  2013cited by this paper
• The prognostic value of apoptotic and proliferative markers in breast cancer

  2013influential reference
• Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice

  2012cited by this paper
• The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

  2012cited by this paper
• Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis.

  2012cited by this paper
• Systems Approaches to Biology and Disease Enable Translational Systems Medicine

  2012cited by this paper
• Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib

  2012cited by this paper
• Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?

  2012cited by this paper
• A Prospective Evaluation of the Effect of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans

  2012cited by this paper
• Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

  2012cited by this paper
• Limitations of Chromogranin A in clinical practice

  2012influential reference
• The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

  2011influential reference
• Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

  2011cited by this paper
• The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

  2011cited by this paper
• Development of a Highly Sensitive and Specific Carboxy-Terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior

  2010cited by this paper
• Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.

  2010cited by this paper
• Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease

  2010cited by this paper
• Relationship Between Quality of Life and Health-Related Measures Including Symptoms, Biochemical Markers And Tumor Burden

  2010cited by this paper
• Biomarkers on a roll

  2010cited by this paper
• Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man.

  2009cited by this paper
• Principal Component Analysis, Hierarchical Clustering, and Decision Tree Assessment of Plasma mRNA and Hormone Levels as an Early Detection Strategy for Small Intestinal Neuroendocrine (Carcinoid) Tumors

  2009cited by this paper
• Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.

  2009cited by this paper
• Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

  2009cited by this paper
• Predictor correlation impacts machine learning algorithms: implications for genomic studies

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.

  2009cited by this paper
• Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Aptasensors for detection of microbial and viral pathogens

  2008cited by this paper
• Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

  2008cited by this paper
• Gastroenteropancreatic neuroendocrine tumours.

  2008cited by this paper
• A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

  2008influential reference
• Advances in multiple analyte profiling.

  2008cited by this paper
• Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR

  2006cited by this paper
• Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors: Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency

  2006cited by this paper
• Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human.

  2006cited by this paper
• Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours

  2006influential reference
• Chromogranin A expression in familial versus sporadic prostate cancer.

  2005cited by this paper
• Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A‐induced bronchoconstriction in asthma patients

  2004cited by this paper
• Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

  2004cited by this paper
• The economic implications of three biochemical screening algorithms for pheochromocytoma.

  2004cited by this paper
• Serum peptide profiles in patients with carcinoid tumors.

  2003cited by this paper
• The chromogranin-secretogranin family.

  2003cited by this paper
• The chromogranin-secretogranin family.

  2003cited by this paper
• Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.

  2000cited by this paper
• Pancreastatin Plasma Levels in Patients with Primary Hyperparathyroidism

  2000cited by this paper
• Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin.

  1999cited by this paper
• Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.

  1995cited by this paper
• Chromogranin A in human hypertension. Influence of heredity.

  1995cited by this paper
• Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.

  1994influential reference
• Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior.

  1993influential reference
• Chromogranin A in uremia: progressive retention of immunoreactive fragments.

  1990cited by this paper
• Plasma Chromogranin A Initial Studies in Human Hypertension

  1985cited by this paper
• A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

  1983influential reference
• The meaning and use of the area under a receiver operating characteristic (ROC) curve.

  1982cited by this paper
• The influence of heredity

  1967cited by this paper
• One Hundred Years

  1933cited by this paper
• Systematic analysis of

  year unknowninfluential reference

• Recent Advances in the Management of Pancreatic Neuroendocrine Tumors: From Diagnosis, Treatment to Biology.

  2026cites this paper
• Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1

  2025cites this paper
• Gastrointestinal and Pancreatic Neuroendocrine Tumors: Pathological Classification, Diagnosis, Treatment, and Challenges

  2025cites this paper
• Serums miR-24-3p and miR-1301-3p as Potential Biomarkers in MEN1 Syndrome

  2025cites this paper
• Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy

  2025cites this paper
• Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review

  2024cites this paper
• Circulating non-coding RNA biomarkers of endocrine tumours

  2024cites this paper
• Serum β-hCG as a Biomarker in Pancreatic Neuroendocrine Tumors: Rethinking Single-Analyte Approach

  2024cites this paper
• The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms

  2024cites this paper
• Virus-associated neuroendocrine cancers: Pathogenesis and current therapeutics.

  2023cites this paper
• The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective

  2023cites this paper
• Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?

  2023cites this paper
• Dual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms

  2023cites this paper
• Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer

  2023cites this paper
• The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities

  2022cites this paper
• miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2

  2022cites this paper
• An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

  2022cites this paper
• Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

  2022cites this paper
• Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics

  2022cites this paper
• Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: “The times they are a changin”

  2021cites this paper
• The role of biomarker in pancreatic neuroendocrine tumor

  2021cites this paper
• Cellular Heterogeneity–Adjusted cLonal Methylation (CHALM) improves prediction of gene expression

  2021cites this paper
• Circulating Biomarkers of GEP and Lung NENs: ‘The Times they are a Changin’

  2021cites this paper
• Multiple endocrine neoplasia type 1 (MEN1) and neuroendocrine neoplasms (NENs).

  2021cites this paper
• Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management

  2021cites this paper
• Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs)

  2021cites this paper
• The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience

  2021cites this paper
• [Update on neuroendocrine tumors].

  2021cites this paper
• Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2

  2020cites this paper
• Local Coverage Determination (LCD): Biomarker Testing for Neuroendocrine Tumors/Neoplasms (L37851)

  2020cites this paper
• Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

  2020cites this paper
• Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors

  2020cites this paper
• Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection

  2020cites this paper
• Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience

  2020cites this paper
• Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest

  2020cites this paper
• Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®

  2020cites this paper
• [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].

  2020cites this paper
• The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual diseaseOK

  2020cites this paper
• A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors

  2020cites this paper
• Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors

  2020cites this paper
• Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix

  2020cites this paper
• MEN1-related PanNETs: identifying unmet clinical needs and future directives.

  2020cites this paper
• Cellular heterogeneity–adjusted clonal methylation (CHALM) provides better prediction of gene expression

  2020cites this paper
• Ruolo diagnostico, prognostico e predittivo di risposta del NETest nelle neoplasie neuroendocrine

  2020cites this paper
• Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead

  2020cites this paper
• NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis

  2020influential citation
• A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.

  2020cites this paper
• Središnja medicinska knjižnica

  2019cites this paper
• CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors

  2019cites this paper
• An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis

  2019cites this paper
• Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies

  2019cites this paper
• Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies

  2019cites this paper
• Neuroendocrine Neoplasms of the Small Bowel and Pancreas

  2019cites this paper
• Clinicopathological correlations of mesenteric fibrosis and evaluation of a novel biomarker for fibrosis detection in small bowel neuroendocrine neoplasms

  2019cites this paper
• The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

  2019cites this paper
• Management of Gastrointestinal Neuroendocrine Tumors

  2019cites this paper
• Sensitivity and Specificity of the NETest: A Validation Study

  2019cites this paper
• Management of NETs in the Precision Medicine Era

  2019cites this paper
• Small intestinal neuroendocrine tumours - Disease models, tumour development, and remedy

  2019cites this paper
• Neuroendocrine Tumors Biomarkers

  2018cites this paper
• A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms

  2018cites this paper
• Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.

  2018cites this paper
• The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.

  2018cites this paper
• Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow‐up after curative surgical resection of well‐differentiated pancreatic neuroendocrine tumors

  2018cites this paper
• Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation

  2018cites this paper
• Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.

  2018cites this paper
• Role of biomarker tests for diagnosis of neuroendocrine tumours

  2018cites this paper
• Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

  2018cites this paper
• Neuroendocrine neoplasia goes molecular — time for a change

  2018cites this paper
• Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis

  2018cites this paper
• Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study

  2018cites this paper
• Effects of intake of breakfast or caffeine‐containing beverages on measurement of circulating chromogranin A in plasma

  2018cites this paper
• Pathology of Neuroendocrine Neoplasms: Morphological, Immunophenotypical, and Circulating Molecular Markers

  2018cites this paper
• Neuroendocrine Gene Transcripts: The Role of Molecular Biomarkers in Diagnosis and Management

  2018cites this paper
• The Molecular Biology of NET: Current Status and Evaluation of Biomarkers for Prediction and Prognosis

  2018cites this paper
• Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies

  2017cites this paper
• Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).

  2017cites this paper
• Preclinics and clinics of neuroendocrine tumors

  2017cites this paper
• Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms

  2017cites this paper
• The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies.

  2017cites this paper
• Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma

  2017cites this paper
• Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

  2017cites this paper
• Biomarkers of neuroendocrine tumors.

  2016cites this paper
• Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.

  2016cites this paper
• Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus

  2016cites this paper
• Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.

  2016cites this paper
• Predictive factors of response to mTOR inhibitors in neuroendocrine tumours.

  2016cites this paper
• Somatostatin Receptor Scintigraphy of Neuroendocrine Tumors of the Abdomen and Pelvis.

  2016cites this paper
• Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

  2016influential citation
• Diagnosis, treatment, and prognosis of bronchopulmonary carcinoid: an analysis of 74 patients

  2016cites this paper
• Chromogranin A: any relevance in neuroendocrine tumors?

  2016cites this paper
• Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms

  2016cites this paper
• NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive

  2016cites this paper
• [Guidelines for gastroenteropancreatic neuroendocrine tumors--what is new? What should be incorporated in daily therapeutic decisions?].

  2015cites this paper
• Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

  2015cites this paper
• Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?

  2015cites this paper
• Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology

  2015cites this paper
• Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status

  2015cites this paper
• The Clinical Utility of a Novel Blood-Based Multi-Transcriptome Assay for the Diagnosis of Neuroendocrine Tumors of the Gastrointestinal Tract

  2015cites this paper
• Molecular genetic findings in small bowel neuroendocrine neoplasms: a review of the literature

  2015cites this paper